Business Economy


Hyderabad, Nov 7 (UNI) With India’s MedTech industry valued at USD14 billion, expected to grow at 14 per cent annually, Venugopala Rao Sankineni, Vice President – Medical Devices Policy & Investments, Telangana Lifesciences, Government of Telangana, on Friday pointed out that 70% of medical devices are still imported, underscoring the need for domestic manufacturing.
After the IT boom, the next big boom will be Medical Devices, he stated.
Delivering a special address on Day 2 of the two-day TG-PackCON 2025 Vision Edition, a Summit for Economic Growth organised by the Confederation of Indian Industry (CII) here, Venugopala Rao outlined Telangana’s four-pronged strategy for growth — attracting investments, fostering innovation, upskilling talent, and building world-class infrastructure for Pharma and Life Sciences.
Emphasising that MSMEs are the backbone of industrial growth, he said the future of life sciences lies at the intersection of biology and technology, highlighting the state’s focus on AI and Digital Health.
He also detailed Telangana’s Digital Health Data Exchange programme, a unified health data portal for advanced digital integration.
He also highlighted the Medical Devices Park at Sultanpur, Patancheru — India’s largest MedTech R&D and manufacturing cluster — and said the second phase is underway, adding that Hyderabad is emerging as a global hub for Medical Tourism.
Dr. Reddanna Pallu, Executive President, Federation of Asian Biotech Association (FABA), noted that India currently contributes only 0.3% of the global biopharma industry and stressed the urgency for accelerated innovation.
He spoke about FABA’s Academy initiative which unites startups, investors and leadership to strengthen the biotech ecosystem, and emphasised the need for large-scale skill development in life sciences.
Gareth Wynn Owen, Deputy High Commissioner, British High Commission, described the India-UK Free Trade Agreement as the broadest and deepest trade treaty signed by the two nations, projecting a 50% surge in bilateral trade from the current £43 billion.
Recognising India’s strength in medical device innovation and the UK’s legacy in MedTech, he said the FTA opens unprecedented avenues for global collaboration.
Earlier, Chakravarthi AVPS, Chairman – TG PackCON 2025 & Chairman & MD, Ecobliss India Pvt Ltd, opened Day 2 with the message: “A future economy cannot be built on linear thinking. Innovation is no longer a choice, it is a responsibility.”
The day commenced with a high-level panel on Pharma & Life Sciences for Economic Growth, where Dr. Vinay Kumar Gupta, Assistant Drug Controller, CDSCO, highlighted the global footprint of Telangana APIs and CDSCO’s role in enabling regulatory readiness.
Girish Kapur, Senior VP & Site Head, United States Pharmacopoeia (USP), stressed that affordability, accessibility, quality and global trust will define India’s pharma future, adding, “Excellence does not happen by accident, it is a journey we are all part of.”
Dr. Ratnakar Palakodeti, President, Innominds, spoke on the central government’s Bio-E3 policy (Economy, Environment, Employment), calling it a holistic ecosystem-driven roadmap.
A high-profile post-lunch session saw diplomats from the UK, Australia, Türkiye, and the Netherlands deliberate on global market opportunities and cross-country collaborations.
Ram Babu Vedantham, Deputy Trade & Investment Commissioner, Netherlands Business Support Office, announced that Heineken is establishing its largest global backend operations hub in Hyderabad—Heineken Business Services India—covering AI, technology, finance and HR functions, to go live by end of 2025.
The summit’s highlight was a Disruptor Talk by Jignesh Talasila, Co-Founder & CEO, Perspective AI, on AI-led disruption in Health Sciences.
Speaking on the theme Molecules to Machines, he demonstrated how AI is transforming drug discovery, citing Google DeepMind’s C2S-Scale system which reduced cancer drug discovery timelines from years to weeks and revealed new therapy pathways using AI models like Gemma.
TG-PackCON 2025 concluded with a strong roadmap for India’s pharmaceutical, medical devices, biotech and AI-driven health sciences future, positioning Telangana at the centre of the next economic and technological revolution.
UNI KNR RN
More News

Brookfield, FedEx to set up GCCs in Mumbai

14 Dec 2025 | 1:39 AM

Mumbai, Dec 13 (UNI) Global alternative asset management and investment firm, Brookfield as well as FedEx Corporation plan to set up Asia’s largest global capability centre (GCC) in Mumbai, Maharashtra Chief Minister Devendra Fadnavis has announced.

see more..

Kerala boasts cost-effective ecosystem of space vendors: Experts at Huddle Global 2025

14 Dec 2025 | 1:02 AM

Thiruvananthapuram, Dec 13 (UNI) Kerala has a very cost-effective and mature ecosystem of space vendors that would help the country become a global vendor in the sector, said experts today at Huddle Global 2025.

see more..

AP: Ponduru Khadi from Srikakulam receives prestigious GI Tag

13 Dec 2025 | 8:22 PM

Srikakulam, (Andhra Pradesh), Dec 13 (UNI) After years of sustained efforts involving extensive documentation, meetings, and follow-ups, Ponduru Khadi, a traditional handwoven fabric from Srikakulam district, has been awarded the prestigious Geographical Indication (GI) tag, union Civil Aviation Minister Kinjarapu Ram Mohan Naidu on Saturday.
Ram Mohan Naidu, also a native of Srikakulam, expressed immense pride over the achievement.

see more..

SBI report flags marginal rise in inflation but sees comfort on prices and rates

13 Dec 2025 | 2:37 PM

New Delhi, Dec 13 (UNI) India’s retail inflation has shown a marginal reversal in November 2025 but remains at a comfortable level, with overall price pressures still muted, according to SBI Research’s latest Ecowrap report released on Saturday here.

see more..

Ozempic ® - world’s most prescribed GLP-1is now available in India

13 Dec 2025 | 4:02 AM

Hyderabad, Dec 12 (UNI) Novo Nordisk, a global healthcare company, on Friday announced the launch of its once-weekly diabetes drug Ozempic® (injectable semaglutide) in India, marking a significant addition to the country’s treatment options for type 2 diabetes.
The therapy, a GLP-1 receptor agonist, is approved as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes mellitus (T2DM).

see more..